Newspatrolling.com News cum Content Syndication Portal Online
Hyderabad, India; June 24, 2026 – Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, today released its latest whitepaper titled “Translational Research Ecosystem: Learnings from the World & Building for India”, highlighting the growing importance of translational science as the critical bridge between discovery and real-world healthcare impact, sitting at the intersection of scientific innovation, multidisciplinary collaboration, funding, regulation, clinical development, policymaking and commercialization.
The comprehensive report brings together actionable insights and strategic recommendations from global and Indian experts across academia, industry, government, not-for-profit organizations, and hospitals. It is based on discussions from the third and recent roundtable convened by Dr. Reddy’s, as a prelude to the Dr. Anji Reddy Memorial Lecture Series.
Translational science is increasingly at the forefront of modern biomedical innovation, bridging the critical gap between scientific discovery and practical application. By accelerating the journey from lab breakthroughs to accessible treatments, translational science plays a significant role in improving health outcomes. However, the pace and scale of this progress are often shaped by a complex interplay of scientific, operational, financial, and regulatory challenges.
The new whitepaper outlines both the systemic barriers in translational research and the significant opportunity for India to strengthen the systems that support the conversion of scientific discoveries into therapies, technologies, and healthcare solutions. While India has established many of the foundational elements required for innovation, it identifies persistent challenges including regulatory approvals, funding gaps, and the need for stronger academic-industry collaboration, that continue to slow progress. Drawing on insights from the global learnings, the whitepaper presents a practical, evidence-based framework to address these gaps and emphasizes that deeper collaboration across academia, industry, healthcare institutions, funding bodies, and government will be essential to accelerate the translation of research into meaningful patient benefit.
Satish Reddy, Chairman, Dr. Reddy’s said: “India stands at a critical inflection point in its innovation journey. To realize our ambition of becoming a global discovery hub, we need a step change, from incremental progress to innovation at scale. This requires stronger translational research pathways to ensure that scientific discoveries translate into meaningful patient impact, alongside accelerated R&D, scaled talent aligned to academic and research structures, and shared infrastructure to support innovation more efficiently. With the right coordination, India has the potential to play an important role in shaping the future of healthcare.”
Key takeaways from the whitepaper:
The roundtable identified several priorities for strengthening India’s translational research ecosystem:
- Bridging the translational gap: While India has developed strong capabilities in scientific research and pharmaceutical manufacturing, the pathway between early-stage discovery and clinical development remains fragmented, causing promising innovations to lose momentum before reaching patients
- Strengthening collaboration across the ecosystem: Greater engagement between academia, industry, healthcare institutions, investors and government agencies will be essential to accelerate the translation of scientific research into healthcare solutions
- Expanding translational funding mechanisms: Sustained and appropriately structured funding is required to support innovations through the long and often complex journey from discovery to development and commercialisation
- Building regulatory capability through structured programme or a centre of excellence for innovation: A globally competitive innovation ecosystem requires regulatory systems that evolve alongside scientific advances and inspire confidence among researchers, developers and investors.
- Unlocking the value of clinical data and healthcare networks: India’s hospitals, patient cohorts and real-world clinical data represent a significant but underutilised research asset that can help accelerate innovation when integrated into translational pathways
- Measuring success through patient outcomes: The ultimate measure of progress should be the number of innovations that reach patients and improve health outcomes, rather than research outputs alone
The panelists of the third roundtable included Dr. Soumya Swaminathan, Chairperson, M S Swaminathan Research Foundation; Prof. V. Ramgopal Rao, Vice Chancellor, BITS Pilani; Dr. Shivkumar Kalyanaraman, CEO, ANRF; Prof. Guido Kroemer, Université Paris Cité; Gustave Roussy Cancer Campus, Paris; Dr. Satya Prakash Dash, CEO, IKP Knowledge Park, Hyderabad; Dr. Murali Ramachandra, CEO, Aurigene Oncology Ltd., Bengaluru; Prof. B.J. Rao, Former Vice-Chancellor, University of Hyderabad; and Dr. Hrishikesh Sarkar, Director, Center for Minimally Invasive Neurosurgery and Neuro-oncology, Continental Hospitals, Hyderabad. The roundtable was chaired by Satish Reddy, Chairman, Dr. Reddy’s and moderated by Anju Ghangurde, Executive Editor (APAC), Citeline.
Dr. Reddy’s instituted the Dr. Anji Reddy Memorial Lecture Series in 2023 to honour the contributions of scientist, entrepreneur, and institution builder Dr. K. Anji Reddy, who founded Dr. Reddy’s Laboratories in 1984. The series is anchored in the core theme of Science, Society, and Sustainability. Since 2024, the company has hosted an annual roundtable ahead of the lecture, convening Nobel Laureates and also leaders from academia, research, science, industry, clinical practice, and public institutions. Each roundtable culminates in a whitepaper capturing key insights, in partnership with Citeline, with
